Given the insufficiency of existing treatment options for these disorders, particularly AD and PD, repurposing already United States Food and Drug Administration (FDA)-approved incretin mimetics could yield a novel therapeutic strategy to more efficiently meet the urgent need to treat neurodegenerative diseases. Here, GCG is linked to neurodegenerative disease.